Skip to main content
SpringerLink
Log in

Pharmacological Therapy for Overactive Bladder

  • Chapter
Female Urology

Part of the book series: Current Clinical Urology ((CCU))

  • 1382 Accesses

Abstract

Multiple classes of drugs, drug therapies, and other pharmacological agents are potentially useful to decrease bladder contractility or decrease sensation and thereby treat overactive bladder (OAB) (see Table 1), but few have been utilized clinically (1). Antimuscarinic agents are the only oral class of drugs that have demonstrated proof of concept in managing this disorder and remain the most commonly prescribed treatment. Since Diokno and Lapides described the properties and application of oxybutynin chloride in the therapy of urinary dysfunction, antimuscarinic therapy has remained the mainstay of therapy for detrusor overactivity and, more recently, the symptom complex known as OAB (2,3). According to the International Continence Society (ICS), OAB is classified as a symptom syndrome and is characterized by urgency, with or without incontinence and sometimes with frequency and nocturia (4). These symptoms are suggestive of detrusor overactivity (that is, urodynamically demonstrable IVCs) but can be attributed to other forms of voiding or urinary dysfunction as well.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andersson K-E, Wein AJ. Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. Pharmacol Rev 2004;56:581–631.

    CAS  PubMed  Google Scholar 

  2. Diokno AC, Lapides J. Oxybutynin: a new drug with analgesic and anticholinergic properties. J Urol 1972;108:307–309.

    CAS  PubMed  Google Scholar 

  3. Rovner ES, Wein AJ. Modern pharmacotherapy of urge urinary incontinence in the USA: tolterodine and oxybutynin. BJU Int 2000;86(suppl 2):44–53.

    CAS  PubMed  Google Scholar 

  4. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167–178.

    PubMed  Google Scholar 

  5. Sellers DJ, Chapple CR, Chess-Williams R. Potential therapeutic targets for treatment of the over-active bladder. World J Urol 2001;19:307–311.

    CAS  PubMed  Google Scholar 

  6. Yoshimura N, Chancellor M. Current and future pharmacological treatment for overactive bladder. J Urol 2002;168:1897–1913.

    CAS  PubMed  Google Scholar 

  7. Andersson KE. The overactive bladder: pharmacologic basis of drug treatment. Urology 1997;50:74–84.

    CAS  PubMed  Google Scholar 

  8. Andersson KE. The concept of uroselectivity. Eur Urol 1998;33(suppl 2):7–11.

    CAS  PubMed  Google Scholar 

  9. Andersson K-E. Current concepts in the treatment of disorders of micturition. Drugs 1988;35:477–494.

    CAS  PubMed  Google Scholar 

  10. Andersson K-E. Advances in the pharmacological control of the bladder. Exp Phys 1999;84:195–213.

    CAS  Google Scholar 

  11. Jensen DJ. Pharmacological studies of the uninhibited neurogenic bladder. II. The influence of cholinergic excitatory and inhibitory drugs on the cystometrogram of neurological patients with normal and uninhibited neurogenic bladder. Acta Neurol Scand 1981;64:175–195.

    PubMed  Google Scholar 

  12. Wein AJ. Neuromuscular dysfunction of the lower urinary tract and its management. In: Campbell’s Urology, 8th ed., (Walsh PC, Retik A, Vaughan ED Jr, et al. eds.), Saunders, Philadelphia, 2002; p. 931–967.

    Google Scholar 

  13. Andersson K-E. Changes in bladder tone during filling: pharmacological aspects. Scand J Urol Nephrol 1999;201:67–72.

    CAS  Google Scholar 

  14. Andersson K-E, Yoshida M. Antimuscarinics and the overactive detrusor-which is the main mechanism of action? Eur Urol 2003;43:1–5.

    CAS  PubMed  Google Scholar 

  15. Yoshida M, Inadome A, Murakami S, et al. Effects of age and muscle stretching on acetylcholine release in isolated human bladder smooth muscle [abstract]. J Urol 2002;167:40.

    Google Scholar 

  16. Caulfield MP. Muscarinic receptors-characterization, coupling and function. Pharmacol Ther 1993;58:319–379.

    CAS  PubMed  Google Scholar 

  17. Chapple CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 2000;55:33–46.

    CAS  PubMed  Google Scholar 

  18. Fetscher C, Fleichman M, Schmidt M, et al. M(3) muscarinic receptors mediate contraction of human urinary bladder. Br J Pharmacol 2002;136:641–643.

    CAS  PubMed  Google Scholar 

  19. Andersson K-E, Appell R, Cardozo L, et al. Pharmacological treatment of urinary incontinence. In Incontinence (Abrams P, Khoury S, Wein AJ, eds.), Health Publication, Plymouth, UK, 1999, pp. 447–486.

    Google Scholar 

  20. Braverman A, Legos J, Young W, et al. M2 receptors in genitourinary smooth muscle pathology. Life Sci 1999;64:432.

    Google Scholar 

  21. Braverman AS, Ruggieri MR, Pontari MA. The M2 muscarinic receptor subtype mediates cholinergic bladder contractions in patients with neurogenic bladder dysfunction. J Urol 2001;165:36.

    Google Scholar 

  22. Chapple CR, Yamanishi T, Chess-Williams R. Muscarinic receptor subtypes and management of the overactive bladder. Urology 2002;60:82–88.

    PubMed  Google Scholar 

  23. Pontari MA, Braverman A, Ruggieri MR. The M2 muscarinic receptor mediates in-vitro bladder contractions from patients with neurogenic bladder dysfunction. Am J Physiol Regul Integr Comp Physiol 2004;286:R874–R880.

    CAS  PubMed  Google Scholar 

  24. Caulfield MP, Birdsall NJ. International Union of Pharmacology XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998;50:279–290.

    CAS  PubMed  Google Scholar 

  25. Agency for Health Care Policy and Research: Urinary Incontinence Guideline Panel. Urinary Incontinence in Adults: Clinical Practice Guidelines (AHCPR publication no. 92–0038), Public Health Service, US Department of Health and Human Services, Rockville, MD, 1992.

    Google Scholar 

  26. Nilvebrant L, Sundquist S, Gilberg PG. Tolterodine is not subtype (M1-M5) selective but exhibits functional bladder selectivity in vivo. Neurourol Urodyn 1996;15:310–311.

    Google Scholar 

  27. Nilvebrant L, Hallen B, Larsson G. Tolterodine-a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci 1997;60:1129–1136.

    CAS  PubMed  Google Scholar 

  28. Nilvebrant L, Andersson KE, Gillberg PG, et al. Tolterodine-a new bladder-selective antimuscarinic agent. Eur J Pharmacol 1997;327:195–207.

    CAS  PubMed  Google Scholar 

  29. Stahl MM, Ekstrom B, Sparf B, et al. Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity. Neurourol Urodyn 1995;14:647–655.

    CAS  PubMed  Google Scholar 

  30. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997;50:90–96.

    CAS  PubMed  Google Scholar 

  31. Chancellor MB, Freedman S. Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clin Drug Invest 2000;19:83–91.

    CAS  Google Scholar 

  32. Kreder KJ, Brubaker L, Mainprize T. Tolterodine is equally effective in patients with mixed incontinence and those with urge incontinence alone. BJU Int 2003;92:418–421.

    CAS  PubMed  Google Scholar 

  33. Van Kerrebroeck P, Kreder K, Jonas U, et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001;57:414–421.

    PubMed  Google Scholar 

  34. Khullar V, Hill S, Laval KU, et al. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology 2004;64:269–274.

    PubMed  Google Scholar 

  35. Landis JR, Kaplan S, Swift S, et al. Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity. J Urol 2004;171:752–756.

    CAS  PubMed  Google Scholar 

  36. Andersson K-E, et al. Pharmacological treatment of urinary incontinence. In Incontinence, 3rd ed. (Abrams P, Cardozo L, Khoury S, et al. eds.), Health Publication, Plymouth, UK, 2005, pp. 809–854.

    Google Scholar 

  37. Madersbacher H, Stohrer M, Richter R, et al. Trospium chloride vs oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia. Br J Urol 1995;75:452–456.

    CAS  PubMed  Google Scholar 

  38. Pietzko A, Dimpfel W, Schwantes U, et al. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol 1994;47:337–343.

    CAS  PubMed  Google Scholar 

  39. Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospum chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 2001;41:636–644.

    CAS  PubMed  Google Scholar 

  40. Hofner K, Oelke M, Machtens S, et al. Trospium chloride-an effective drug in the treatment of overactive bladder and detrusor hyperreflexia. World J Urol 2001;19:336–343.

    CAS  PubMed  Google Scholar 

  41. Hawthorn M, Chapple CR, Cock M, et al. Urothelium derived inhibitory factor(s) influences on detrusor muscle contractility in vitro. Br J Pharmacol 2000;129:416–419.

    CAS  PubMed  Google Scholar 

  42. Cardozo L, Chapple CR, Toozs-Hobson P, et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial. BJU Int 2000;85:659–664.

    CAS  PubMed  Google Scholar 

  43. Alloussi S, Laval KU, Ballering-Bruhl B, et al. Trospium chloride (Spasmo-lyt) in patients with motor urge syndrome (detrusor instability): a double-blind, randomised, multicentre, placebo-controlled study. J Clin Res 1998;1:439–451.

    Google Scholar 

  44. Stohrer M, Bauer P, Giannetti BM, et al. Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia to spinal cord injuries. A multicentre placebo-controlled double-blind trial. Urol Int 1991;47:138–143.

    Article  CAS  PubMed  Google Scholar 

  45. Rudy D, et al. A multicenter, randomized, placebo-controlled trial of trospium chloride in overactive bladder patients [abstract]. Presented at: annual meeting of the International Continence Society; 2004. Paris, France, August 25–27, 2004.

    Google Scholar 

  46. Zinner N, Gittelman M, Harris R, et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004;171:2311–2315.

    CAS  PubMed  Google Scholar 

  47. Halaska M, Ralph G, Wiedemann A, et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 2003;20:392–399.

    CAS  PubMed  Google Scholar 

  48. Juneman K, et al. Efficacy and tolerability of trospium chloride and tolterodine in 234 patients with urge syndrome [abstract]. Neurourol Urodyn 2000;19:488–490.

    Google Scholar 

  49. Newgreen DT, Anderson DWP, Carter AJ. Darifenacin: a novel bladder-selective agent for the treatment of urge incontinence [abstract]. Neurourol Urodyn 1995;14:95.

    Google Scholar 

  50. Wallis RM, Napier CM. Muscarinic antagonists in development for disorders of smooth muscle function. Life Sci 1999;64:395–401.

    CAS  PubMed  Google Scholar 

  51. Rosario DJ, Cutinha PE, Chapple CR. The effects of single-dose darifenacin on cystometric parameters and salivary flow in patients with urge incontinence secondary to detrusor instability [abstract]. Eur Urol 1996;30:240.

    Google Scholar 

  52. Rosario DJ, Smith DJ, Radley SC, et al. Pharmacodynamics of anticholinergic agents measured by ambulatory urodynamic monitoring: a study of methodology. Neurourol Urodyn 1999;18:223–233.

    CAS  PubMed  Google Scholar 

  53. Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well tolerated once-daily treatment for overactive bladder. Eur Urol 2004;45:420–429.

    CAS  PubMed  Google Scholar 

  54. Steers W, Corcos J, Foote J, et al. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. BJU Int 2005;95:580–586.

    CAS  PubMed  Google Scholar 

  55. Cardozo L, Dixon A. Increased warning time with darifenacin: a new concept in the management of urinary urgency. J Urol 2005;173:1214–1218.

    PubMed  Google Scholar 

  56. Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol 2005;173:493–498.

    PubMed  Google Scholar 

  57. Hegde SS, Mammen M, Jasper JR. Antimuscarinics for the treatment of overactive bladder: current options and emerging therapies. Curr Opin Invest Drugs 2004;5:40–49.

    CAS  Google Scholar 

  58. Ikeda K, Kobayashi S, Suzuki M, et al. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol 2002;366:97–103.

    CAS  PubMed  Google Scholar 

  59. Kobayashi S, Ikeda K, Miyata K. Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells. Life Sci 2004;74:843–853.

    CAS  PubMed  Google Scholar 

  60. Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. Journal of Urology 2004;172:1919–1924.

    CAS  PubMed  Google Scholar 

  61. Chapple CR, Arano P, Bosch JL, et al. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo-and tolterodine-controlled phase 2 dose-finding study. BJU Int 2004;93:71–77.

    CAS  PubMed  Google Scholar 

  62. Chapple CR, Rechberger T, Al Shukri S, et al. Randomized, double-blind placebo-and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004;93:303–310.

    CAS  PubMed  Google Scholar 

  63. Buyse G, Waldeck K, Verpoorten C, et al. Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects to reduced first pass metabolism. J Urol 1998;160:892–896.

    CAS  PubMed  Google Scholar 

  64. Hughes KM, Lang JC, Lazare R, et al. Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica 1992;22:859–869.

    CAS  PubMed  Google Scholar 

  65. Dmochowski RR, Staskin DR. Advances in drug delivery: improved bioavailability and drug effect. Curr Urol Rep 2002;3:439–444.

    PubMed  Google Scholar 

  66. Gupta S, Sathyan G, Mori T. New perspectives on the overactive bladder: pharmacokinetics and bioavailability. Urology 2002;60:78–80.

    PubMed  Google Scholar 

  67. Donnellan CA, Fook L, McDonald P, et al. Oxybutynin and cognitive dysfunction. BMJ 1997;315:1363–1364.

    CAS  PubMed  Google Scholar 

  68. Katz IR, Sands LP, Bilker W, et al. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 1998;46:8–13.

    CAS  PubMed  Google Scholar 

  69. Thuroff J, Abrams P, Chartier-Kasher E, et al. Medical treatment and medical side effects in urinary incontinence in the elderly. World J Urol 1998;16:548–561.

    Google Scholar 

  70. Gupta SK, Sathyan G. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol 1999;39:289–296.

    CAS  PubMed  Google Scholar 

  71. Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clinic Proc 2001;76:358–363.

    CAS  Google Scholar 

  72. Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clinic Proc 2003;78:687–695.

    CAS  Google Scholar 

  73. Anderson RU, Mobley D, Blank B, et al. Once daily controlled vs immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. J Urol 1999;161:1809–1812.

    CAS  PubMed  Google Scholar 

  74. Versi E, Appell R, Mobley D, et al. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. Obst Gynecol 2000;95:718–721.

    CAS  Google Scholar 

  75. Collas D, Malone-Lee JG. The pharmacokinetic properties of rectal oxybutynin-a possible alternative to intravesical administration. Neurourol Urodyn 1997;16:346–350.

    Google Scholar 

  76. Winkler HA, Sand PK. Treatment of detrusor instability with oxybutynin rectal suppositories. Int Urogynecol J 1998;9:100–102.

    CAS  Google Scholar 

  77. Davila GW, Daugherty CA, Sanders SW, et al. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001;166:140–145.

    CAS  PubMed  Google Scholar 

  78. Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002;168:580–586.

    CAS  PubMed  Google Scholar 

  79. Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine vs placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003;62:237–242.

    PubMed  Google Scholar 

  80. Jonas U, Petri E, Kissel J. Effect of flavoxate on uninhibited detrusor muscle. Eur Urol 1979;5:106–109.

    CAS  PubMed  Google Scholar 

  81. Briggs RS, Castleden CM, Asher MJ. The effect of flavoxate on uninhibited detrusor contractions and urinary incontinence in the elderly. J Urol 1980;123:665–666.

    CAS  PubMed  Google Scholar 

  82. Chapple CR, Parkhouse H, Gardener C, et al. Double-blind placebo controlled crossover study of flavoxate in the treatment of idiopathic detrusor instability. Br J Urol 1990;66:491–494.

    CAS  PubMed  Google Scholar 

  83. Wein AJ. Pharmacology of incontinence. Urol Clin North Am 1995;22:557–577.

    CAS  PubMed  Google Scholar 

  84. Baldessarini RJ. Drugs and the treatment of psychiatric disorders: depression and mania. In: Goodman and Gilman’s The Pharmacological Basis of Therapeutics (Hardman JG, Limbird LE, Molinoff PB, et al., eds.), McGraw-Hill Health Professions Division, New York, 1996, pp. 431–461.

    Google Scholar 

  85. Richelson E. Pharmacology of antidepressants-characteristics of the ideal drug. Mayo Clinic Proc 1994;69:1069–1081.

    CAS  Google Scholar 

  86. Levin RM, Staskin DR, Wein AJ. Analysis of the anticholinergic and musculotropic effects of desmethylimipramine on the rabbit urinary bladder. Urol Res 1983;11:259–262.

    CAS  PubMed  Google Scholar 

  87. Levin RM, Wein AJ. Comparative effects of five tricyclic compounds on the rabbit uirnary bladder. Neurourol Urodynamics 1984;3:127–135.

    CAS  Google Scholar 

  88. Olubadewo J. The effect of imipramine on rat detrusor muscle contractility. Arch Int Pharmacodyn Ther 1980;245:84–94.

    CAS  PubMed  Google Scholar 

  89. Andersson KE. Treatment of overactive bladder: other drug mechanisms. Urology 2000;55:51–57.

    CAS  PubMed  Google Scholar 

  90. Espy MJ, Du HJ, Downie JW. Serotonergic modulation of spinal ascending activity and sacral reflex activity evoked by pelvic nerve stimulation in cats. Brain Res 1998;798:101–108.

    Google Scholar 

  91. Castleden CM, George CF, Renwick AG, et al. Imipramine-a possible alternative to current therapy for urinary incontinence in the elderly. J Urol 1981;125:318–320.

    CAS  PubMed  Google Scholar 

  92. Cole AT, Fried FA. Favorable experiences with imipramine in the treatment of neurogenic bladder. J Urol 1972;107:44–45.

    CAS  PubMed  Google Scholar 

  93. Dykstra DD, Sidi AA, Scott AB, et al. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 1988;139:919–922.

    CAS  PubMed  Google Scholar 

  94. Phelan MW, Franks M, Somogyi GT, et al. Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol 2001;165:1107–1110.

    CAS  PubMed  Google Scholar 

  95. Harper M, Fowler C, Dasgupta P. Botulinum toxin and its applications in the lower urinary tract. BJU 2004;93:702–706.

    CAS  Google Scholar 

  96. Reitz A, Schurch B. Intravesical therapy options for neurogenic detrusor overactivity. Spinal Cord 2004;42:267–272.

    PubMed  Google Scholar 

  97. Schurch B, Stohrer M, Kramer G, et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000;164:692–697.

    CAS  PubMed  Google Scholar 

  98. Rapp D, et al. Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience. Urology 2004;63:1071–1075.

    PubMed  Google Scholar 

  99. Kessler T, et al. Botulinum-A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity. Neurourol Urodyn 2005;24:236.

    Google Scholar 

  100. Werner M, et al. Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study. Am J Obstet Gynecol 2005;192:1740.

    Google Scholar 

  101. Maggi CA, Barbanti G, Santicioli P, et al. Cystometric evidence that capsaicin sensitive nerves modulate the afferent branch of micturition reflex in humans. J Urol 1989;142:150–154.

    CAS  PubMed  Google Scholar 

  102. Maggi CA. Therapeutic potential of capsaicin-like molecules: studies in animals and humans. Life Sci 1992;51:1777–1781.

    CAS  PubMed  Google Scholar 

  103. Maggi CA. Capsaicin and primary afferent neurons: from basic science to human therapy? J Auton Nerv Syst 1993;33:1–14.

    Google Scholar 

  104. Dray A. Mechanism of action of capsaicin-like molecules on sensory neurons. Life Sci 1992;51:1759–1765.

    CAS  PubMed  Google Scholar 

  105. Caterina JJ, Schumacher MA, Tominaga M, et al. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997;389:816–824.

    CAS  PubMed  Google Scholar 

  106. Caterina MJ, Rosen TA, Tominaga M, et al. A capsaicin-receptor homologue with a high threshold for noxious heat. Nature 1999;398:436–441.

    CAS  PubMed  Google Scholar 

  107. DeRidder D, Baert L. Vanilloids and the overactive bladder. BJU Int 2000;86:172–180.

    CAS  Google Scholar 

  108. DeSeze M, Wiart L, Ferriere J, et al. Intravesical instillation of capsaicin in urology: a review of the literature. EurUrol 1999;36:267–277.

    CAS  Google Scholar 

  109. Chancellor MB, de Groat WC. Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder. J Urol 1999;162:3–11.

    CAS  PubMed  Google Scholar 

  110. Moehrer B, Hextall A, Jackson S. Oestrogens for urinary incontinence in women. Cochrane Database Syst Rev (1), 2003.

    Google Scholar 

  111. Hendrix SL, Cochrane BB, Nygaard IE, et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA 2005;293:935–948.

    CAS  PubMed  Google Scholar 

  112. Hay-Smith J, Herbison P, Ellis G, et al. Anticholinergic drugs vs placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev CD003781, 2002.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Columbia University School of Medicine, New York, NY

    Eric S. Rovner MD

Authors
  1. H. Mallory Reeves MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric S. Rovner MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alan J. Wein MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Section of Female Urology and Voiding Dysfunction The Glickman Urological Institute, The Cleveland Clinic, Cleveland, Ohio

    Howard B. Goldman MD  & Sandip P. Vasavada MD  & 

  2. Department of Urology and Reproductive Biology, CASE School of Medicine, Cleveland, Ohio

    Howard B. Goldman MD

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Reeves, H.M., Rovner, E.S., Wein, A.J. (2007). Pharmacological Therapy for Overactive Bladder. In: Goldman, H.B., Vasavada, S.P. (eds) Female Urology. Current Clinical Urology. Humana Press. https://doi.org/10.1007/978-1-59745-368-4_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-368-4_12

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-701-3

  • Online ISBN: 978-1-59745-368-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation